Bank of America’s chief executive has said the company spends $250 million a year on GLP-1 drugs for its employees as the weight-loss medications surge in popularity.
U.S. adults currently taking a GLP-1 medication for weight loss, such as Ozempic or Wegovy, increased to 11 percent this year, up from 3 percent in 2024, according to a Gallup poll released last month.